Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Part of paid clinical trials in Tucson, Arizona.

Sponsor
University of Arizona
Study ID
NCT02623920
Phase
PHASE2
Status
Withdrawn

Conditions

  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Grey Zone Lymphoma
  • High Grade B Cell Lymphoma
  • Marginal Zone Lymphoma
  • Mediastinal Large B-cell Lymphoma
  • Small Lymphocytic Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Brentuximab — DRUG
    Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  • Bendamustine — DRUG
    Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
  • Rituximab — DRUG
    Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Study Details

This phase II trial studies how well brentuximab vedotin, bendamustine, and rituximab work in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, use antibody to target chemotherapy in cancer cells. Drugs used in chemotherapy, such as bendamustine, work in different ways to kill cancer cells. Monoclonal antibodies, such as rituximab, kill the cancer cells directly, but also harness the immune system to kill the cancer cells. Adding brentuximab to rituximab may improve response rates in CD30 positive, CD20 positive Relapsed Refactory NHL.

Key Dates

Start date
Dec 16, 2015
Status verified
May 2017
Primary completion
May 17, 2017
Completion
May 17, 2017

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Brentuximab, Bendamustine, Rituximab
    Brentuximab Vedotin in Combination with Bendamustine and Rituximab

Primary Outcome Measure

CR rate [ Time Frame: Up to 2 years after completion of study treatment ]

Locations (1)

FacilityCityStateZIPSite coordinators
Arizona Cancer Center at UMC NorthTucsonArizona85724-

Find similar trials in Tucson, AZ

By research site
Arizona Cancer Center at UMC North· Tucson, AZ

Related Studies